Cost of Scots’ fat jabs rockets… thanks to Trump’s ‘America First’ policy

Cost of Scots’ fat jabs rockets… thanks to Trump’s ‘America First’ policy

January 25, 2026 discoverhiddenusacom Health

The financial burden of addressing obesity in Scotland has reached a record high, a situation partially linked to a policy shift enacted by the United States government. The country’s National Health Service (NHS) is currently spending nearly £3 million each month on weight-loss injections, according to recent data.

Rising Costs and Increased Demand

Demand for these injections has surged since they became available on prescription a year ago, as individuals in Scotland seek assistance with weight management. In September, almost 20,000 prescriptions for Mounjaro, Ozempic, and Wegovy were filled. However, the cost to the Scottish health service increased significantly not only due to this heightened demand but also due to a policy implemented in the US.

The Impact of US Policy

A directive from former President Donald Trump instructed American pharmaceutical companies to prioritize sales to US citizens and healthcare providers at the lowest available prices. As a result, Eli Lilly, the manufacturer of Mounjaro, increased prices in the UK starting in September, after previously offering the drug at a lower cost than in the US. This price hike had an immediate and substantial impact on the Scottish NHS budget.

Did You Know? In September, the average cost of a single Mounjaro injection to the NHS more than doubled, rising from £99 to £215.

Analysis reveals that the average cost of a Mounjaro injection to the NHS more than doubled overnight, increasing from £99 to £215. The Scottish Government has reportedly requested that UK ministers work to maintain lower drug prices, emphasizing that protecting the NHS in Scotland is a priority in any US-UK negotiations.

Medical Perspectives

Medical professionals emphasize the continued importance of weight-loss injections in combating obesity. Dr. Naveed Sattar, professor of metabolic medicine at the University of Glasgow, stated that these medications not only aid in weight loss but also significantly reduce the risk of various health issues, including kidney disease, heart failure, heart attacks, sleep apnea, liver diseases, and knee pain. He believes prescriptions for these drugs represent a sound investment.

Expert Insight: The increased cost of these medications highlights the complex interplay between international trade policies and domestic healthcare budgets, potentially creating challenges for sustainable access to vital treatments.

Prescription numbers and associated costs have steadily risen. In January, 8,207 injections were prescribed at a cost of £692,000. By August, these figures had increased to 15,648 prescriptions and £1.4 million, respectively. However, September saw a disproportionate jump, with 18,251 prescriptions totaling £2.71 million.

Mounjaro is currently the most frequently prescribed weight-loss injection in Scotland. Ozempic and Wegovy, manufactured by a Danish company, were not affected by the US price increase.

Frequently Asked Questions

What caused the increase in the cost of weight-loss injections?

The cost increase was due to a combination of increased demand and a price hike by Mounjaro manufacturer Eli Lilly, following a US policy that prioritized domestic sales at lower prices.

Which weight-loss injections were most affected by the price increase?

Mounjaro was the primary injection affected by the price increase, as it is manufactured by an American company subject to the US policy. Ozempic and Wegovy, produced by a Danish firm, were not impacted.

What is the Scottish Government’s response to the rising costs?

The Scottish Government has requested that UK ministers attempt to negotiate lower drug prices and has stated that protecting the NHS in Scotland is a key consideration in US-UK negotiations.

As healthcare costs continue to evolve, how might international policies impact access to essential medications in the future?

, , ,